Ligand Pharmaceuticals Incorporated (LGND): Price and Financial Metrics


Ligand Pharmaceuticals Incorporated (LGND): $126.61

-1.19 (-0.93%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add LGND to Watchlist
Sign Up

Industry: Biotech


Ranked

of 485

in industry

LGND POWR Grades


  • Quality is the dimension where LGND ranks best; there it ranks ahead of 71.82% of US stocks.
  • The strongest trend for LGND is in Value, which has been heading down over the past 31 weeks.
  • LGND ranks lowest in Sentiment; there it ranks in the 16th percentile.

LGND Stock Summary

  • The price/operating cash flow metric for Ligand Pharmaceuticals Inc is higher than 88.96% of stocks in our set with a positive cash flow.
  • Over the past twelve months, LGND has reported earnings growth of -222.49%, putting it ahead of merely 9.57% of US stocks in our set.
  • As for revenue growth, note that LGND's revenue has grown 89.53% over the past 12 months; that beats the revenue growth of 93.4% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to Ligand Pharmaceuticals Inc, a group of peers worth examining would be PCRX, MMX, UTHR, EXK, and AJRD.
  • Visit LGND's SEC page to see the company's official filings. To visit the company's web site, go to www.ligand.com.

LGND Price Target

For more insight on analysts targets of LGND, see our LGND price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $213.57 Average Broker Recommendation 1.56 (Moderate Buy)

LGND Stock Price Chart Interactive Chart >

Price chart for LGND

LGND Price/Volume Stats

Current price $126.61 52-week high $219.75
Prev. close $127.80 52-week low $78.26
Day low $123.49 Volume 329,600
Day high $127.85 Avg. volume 394,706
50-day MA $131.29 Dividend yield N/A
200-day MA $121.79 Market Cap 2.11B

Ligand Pharmaceuticals Incorporated (LGND) Company Bio


Ligand Pharmaceuticals develops therapies that address the unmet medical needs of patients for a range of diseases, including hepatitis, multiple myeloma, muscle wasting, Alzheimer’s disease, dyslipidemia, diabetes, anemia, epilepsy, focal segmental glomerulosclerosis, and osteoporosis. The company was founded in 1987 and is based in La Jolla, California.

LGND Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$126.61$26.68 -78%

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Ligand Pharmaceuticals Inc. To summarize, we found that Ligand Pharmaceuticals Inc ranked in the 20th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 78.17%. In terms of the factors that were most noteworthy in this DCF analysis for LGND, they are:

  • 85% of the company's capital comes from equity, which is greater than 60.28% of stocks in our cash flow based forecasting set.
  • Ligand Pharmaceuticals Inc's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than only 0% of US stocks with positive free cash flow.
  • The company's cost of debt, derived from its interest coverage, tax rate, and market capitalization, is greater than 62.89% of stocks in its sector (Healthcare).


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-79%
1%-78%
2%-78%
3%-78%
4%-78%
5%-78%

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as LGND, try ARWR, SRDX, ILMN, EW, and MD.


LGND Latest News Stream


Event/Time News Detail
Loading, please wait...

LGND Latest Social Stream


Loading social stream, please wait...

View Full LGND Social Stream

Latest LGND News From Around the Web

Below are the latest news stories about Ligand Pharmaceuticals Inc that investors may wish to consider to help them evaluate LGND as an investment opportunity.

Ligand (LGND) Down 14% Since Last Earnings Report: Can It Rebound?

Ligand (LGND) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo | June 2, 2021

We Think Some Shareholders May Hesitate To Increase Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) CEO Compensation

In the past three years, the share price of Ligand Pharmaceuticals Incorporated ( NASDAQ:LGND ) has struggled to grow...

Yahoo | May 29, 2021

Estimating The Fair Value Of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

Today we will run through one way of estimating the intrinsic value of Ligand Pharmaceuticals Incorporated...

Yahoo | May 5, 2021

Ligand (LGND) Q1 Earnings Top, Bad Weather Hits Captisol Sales

Ligand (LGND) reports mixed first-quarter 2021 numbers with earnings beating estimates but revenues missing the same. Stock down.

Yahoo | May 4, 2021

Ligand's Revenue Soars in Q1 Thanks to Gilead's COVID Drug

The drugmaker is also looking for its highest sales ever in 2021 in large part because of remdesivir.

Yahoo | May 4, 2021

Read More 'LGND' Stories Here

LGND Price Returns

1-mo 2.48%
3-mo -20.84%
6-mo 27.32%
1-year 8.92%
3-year -36.42%
5-year 10.18%
YTD 27.31%
2020 -4.64%
2019 -23.15%
2018 -0.90%
2017 34.76%
2016 -6.28%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.3955 seconds.